Growth Metrics

HeartSciences (HSCS) Net Income towards Common Stockholders (2021 - 2026)

HeartSciences filings provide 6 years of Net Income towards Common Stockholders readings, the most recent being -$2.0 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 21.97% to -$2.0 million in Q1 2026 year-over-year; TTM through Jan 2026 was -$8.5 million, a 1.73% increase, with the full-year FY2025 number at -$8.9 million, down 32.93% from a year prior.
  • Net Income towards Common Stockholders hit -$2.0 million in Q1 2026 for HeartSciences, up from -$2.4 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.2 million in Q1 2022 to a low of -$2.6 million in Q1 2025.
  • Median Net Income towards Common Stockholders over the past 5 years was -$1.9 million (2024), compared with a mean of -$1.9 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: tumbled 109.25% in 2022 and later grew 21.97% in 2026.
  • HeartSciences' Net Income towards Common Stockholders stood at -$1.8 million in 2022, then grew by 3.28% to -$1.7 million in 2023, then fell by 20.26% to -$2.1 million in 2024, then decreased by 11.9% to -$2.4 million in 2025, then increased by 15.41% to -$2.0 million in 2026.
  • The last three reported values for Net Income towards Common Stockholders were -$2.0 million (Q1 2026), -$2.4 million (Q4 2025), and -$2.1 million (Q3 2025) per Business Quant data.